🇺🇸 FDA
Pipeline program

AZD1222

D8111C00010

Approved mab terminated

Quick answer

AZD1222 for COVID-19, SARS-CoV-2 is a Approved program (mab) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
COVID-19, SARS-CoV-2
Phase
Approved
Modality
mab
Status
terminated

Clinical trials